ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

ClinicalTrials.gov ID: NCT00546572

Public ClinicalTrials.gov record NCT00546572. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 8:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Active-Controlled, Modified Double-Blind Trial, Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) Compared To A 23-Valent Pneumococcal Polysaccharide (23vPS) Vaccine in Ambulatory Elderly Individuals Aged 70 Years And Older Who Received One Dose of 23vPS At Least 5 Years Prior To Study Enrollment

Study identification

NCT ID
NCT00546572
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Enrollment
938 participants

Conditions and interventions

Interventions

  • 13 valent Pneumococcal Conjugate Vaccine Biological
  • 23vPS Biological

Biological

Eligibility (public fields only)

Age range
70 Years and older
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 31, 2007
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010
Last update posted
Jul 13, 2011

2007 – 2010

United States locations

U.S. sites
51
U.S. states
25
U.S. cities
46
Facility City State ZIP Site status
Pfizer Investigational Site Mobile Alabama 36608
Pfizer Investigational Site Mesa Arizona 85203
Pfizer Investigational Site Mesa Arizona 85213
Pfizer Investigational Site Fountain Valley California 92708
Pfizer Investigational Site Denver Colorado 80262
Pfizer Investigational Site Waterbury Connecticut 06708
Pfizer Investigational Site Clearwater Florida 33761
Pfizer Investigational Site Coral Gables Florida 33134
Pfizer Investigational Site Jacksonville Florida 32216
Pfizer Investigational Site Pinellas Park Florida 33781
Pfizer Investigational Site Tampa Florida 33614
Pfizer Investigational Site Atlanta Georgia 30305
Pfizer Investigational Site Atlanta Georgia 30328
Pfizer Investigational Site Stockbridge Georgia 30328
Pfizer Investigational Site Shawnee Mission Kansas 66128
Pfizer Investigational Site Lexington Kentucky 40536
Pfizer Investigational Site Baltimore Maryland 21209
Pfizer Investigational Site Minneapolis Minnesota 55417
Pfizer Investigational Site Rochester Minnesota 55905
Pfizer Investigational Site St Louis Missouri 63104
Pfizer Investigational Site St Louis Missouri 63141
Pfizer Investigational Site Butte Montana 59701
Pfizer Investigational Site Las Vegas Nevada 89146
Pfizer Investigational Site Rochester New York 14642
Pfizer Investigational Site Cary North Carolina 27511
Pfizer Investigational Site Charlotte North Carolina 28209
Pfizer Investigational Site Durham North Carolina 27705
Pfizer Investigational Site Durham North Carolina 27710
Pfizer Investigational Site Hickory North Carolina 28601
Pfizer Investigational Site Raleigh North Carolina 27612
Pfizer Investigational Site Salisbury North Carolina 28144
Pfizer Investigational Site Winston-Salem North Carolina 27103
Pfizer Investigational Site Fargo North Dakota 58103
Pfizer Investigational Site Cincinnati Ohio 45229
Pfizer Investigational Site Cincinnati Ohio 45236
Pfizer Investigational Site Cleveland Ohio 44195
Pfizer Investigational Site Corvallis Oregon 97330
Pfizer Investigational Site Eugene Oregon 97401
Pfizer Investigational Site Carnegie Pennsylvania 15106
Pfizer Investigational Site Downington Pennsylvania 19335
Pfizer Investigational Site Grove City Pennsylvania 16127
Pfizer Investigational Site Penndel Pennsylvania 19047
Pfizer Investigational Site Pittsburgh Pennsylvania 15241
Pfizer Investigational Site Upper Saint Clair Pennsylvania 15241
Pfizer Investigational Site Greer South Carolina 29651
Pfizer Investigational Site Mt. Pleasant South Carolina 29464
Pfizer Investigational Site Bristol Tennessee 37620
Pfizer Investigational Site Nashville Tennessee 37232
Pfizer Investigational Site Austin Texas 78705
Pfizer Investigational Site Norfolk Virginia 23507
Pfizer Investigational Site Seattle Washington 998101

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 7 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00546572, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 13, 2011 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00546572 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →